Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof
AssigneeInsmed Incorporated
InventorsRonald Gunn, Geoffrey Allan
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of reducing serum lipids in insulin resistant subjects comprising administration of synergistically effective amounts of D-chiro-inositol and lipid lowering medications. The present invention provides methods to treat a hyperlipidemic subject with insulin resistance comprising administration of D-chiro-inositol and a lipid lowering compound, either as concurrent single agents or as a combined composition. The methods and compositions of the present invention are particularly efficacious in treating insulin resistant subjects with a fasting blood glucose level of less than or equal to 180 mg/dL.
Claims20
A method of treating dyslipidemia in a subject in need thereof comprising:
- (a) administration of synergistically effective amount of D-chiro-inositol, or a derivative or metabolite thereof, or a compound containing D-chiro-inositol or a derivative or metabolite thereof;
- and
- (b) administration of a synergistically effective amount of a lipid lowering compound,
- wherein said D-chiro-inositol, or derivative or metabolite thereof, or compound containing D-chiro-inositol or derivative or metabolite thereof is selected from the group consisting of:
- D-chiro-inositol;
- D-chiro-inositol-phosphates;
- pinitol;
- amino disaccharide insulin mimetics, ciceritol, 1D-2-O-alpha-D-galactopyranose, and a fagopyritol, and
- wherein the synergistically effective amounts of said D-chiro-inositol, or derivative or metabolite thereof, or compound containing D-chiro-inositol or derivative or metabolite thereof and the lipid lowering compound are administered as a concurrent regimen.
A method of treating dyslipidemia in a subject in need thereof comprising:
- (a) administration of a synergistically effective amount of D-chiro-inositol, or a derivative or metabolite thereof, or a compound containing D-chiro-inositol or a derivative or metabolite thereof, in the range of 3 mg/kg to about 300 mg/kg, said D-chiro-inositol, or derivative or metabolite thereof, or compound containing D-chiro-inositol or derivative or metabolite thereof being selected from the group consisting of:
- D-chiro-inositol;
- D-chiro-inositol-phosphates;
- pinitol;
- amino disaccharide insulin mimetics, ciceritol, 1D-2-O-alpha-D-galactopyranose, and a fagopyritol;
- and
- (b) administration of a synergistically effective amount of a lipid lowering compound,
- wherein the synergistically effective amounts of D-chiro-inositol, or derivative or metabolite thereof, or compound containing D-chiro-inositol or derivative or metabolite thereof, and the lipid lowering compound are administered concurrently.
A method of treating dyslipidemia in a subject in need thereof comprising:
- (a) administration of D-chiro-inositol in the synergistic range of about 3 mg/kg to about 20 mg/kg;
- and
- (b) administration of a synergistically effective lipid lowering compound;
- wherein the subject suffers from type 2 diabetes with a fasting blood glucose level of less than or equal to 180 mg/dL, and wherein the synergistically effective amounts of D-chiro-inositol and the lipid lowering compound are administered concurrently.
A composition comprising:
- (a) a pharmaceutically effective amount in the synergistic range of about 100 mg to about 4000 mg of D-chiro-inositol, or a derivative or metabolite thereof, or a compound containing D-chiro-inositol or a derivative or metabolite thereof;
- and
- (b) a pharmaceutically effective amount of a synergistically effective lipid lowering compound,
- wherein said D-chiro-inositol, or derivative or metabolite thereof, or compound containing D-chiro-inositol or derivative or metabolite thereof is selected from the group consisting of:
- D-chiro-inositol;
- D-chiro-inositol-phosphates;
- pinitol;
- amino disaccharide insulin mimetics, ciceritol, 1D-2-O-alpha-D-galactopyranose, and a fagopyritol.
Dependencies are inferred from the claim text.